Aiosyn, Radboud University medical centre and Pathologie-DNA have received a €1.3m ($1.4m) EFRO-OOST grant to boost artificial intelligence (AI) technology development for breast and skin cancer diagnostics.

Through the AIRAT project, the three organisations will work together to launch CE-marked deep learning algorithms for automated mitosis detection into the market.

Under the project, Aiosyn will be responsible for the further development and validation of AI-driven algorithms designed for the diagnosis of breast and skin cancer.

Pathologists can precisely predict tumour growth and understand patients’ prognosis using AI-based digital biomarkers.

It helps decrease observer variability and enhance the consistency of diagnoses while improving patient outcomes.

Aiosyn chief innovation officer Wouter Bulten said: “At Aiosyn, we recognise the critical role pathologists play in diagnostics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Through close collaboration, this EFRO grant enables us to further develop AI tools that support pathologists and enhance pathology practice.”

Aiosyn’s algorithms are set to be integrated into the current digital pathology workflows such as Sectra.

AI-driven solutions are expected to make significant advancements in evaluating and managing cancer patients globally.

Aiosyn CSO and Radboud University medical centre professor Jeroen van der Laak said: “Once you have decided which problem to solve and have collected all required data, developing AI for Pathology is doable.

“But collecting high-quality data is tough and getting the AI to a level that truly creates patient value is even tougher. In our AIRAT project we will tackle those challenges: collect multi-center data and move the developed AI forward to a certified product, ready to support pathologists.”